Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1005-1010

  Tsutani, Y ^a   Takuwa, T ^b   Miyata, Y ^a   Fukuoka, K ^b   Hasegawa, S ^b   Nakano, T ^b   Okada, M ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Metabolic response; Neoadjuvant chemotherapy; Positron emission tomography

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; PEMETREXED;

ADULT; ARTICLE; BRONCHOPLEURAL FISTULA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHYLOTHORAX; CLINICAL ARTICLE; DIAPHRAGM HERNIA; DRUG RESPONSE; EXTRAPLEURAL PNEUMONECTOMY; FEMALE; HEART DISEASE; HEART FAILURE; HEART HERNIATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTRATHORACIC HEMORRHAGE; LUNG RESECTION; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA EMPYEMA; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RESPIRATORY FAILURE; TUMOR REGRESSION;

AGED; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84875592774     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds537     Document Type: Article

References (23)

1. Peto J, Decarli A, La Vecchia C et al.. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672.
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-218.
3. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004; 4: 469-477.
4. Nakano T. Current therapies for malignant pleural mesothelioma. Environ Health Prev Med 2008; 13: 75-83.
5. Singhal S, Kaiser LR. Malignant mesothelioma: options for management. Surg Clin N Am 2002; 82: 797-831.
6. Yamanaka T, Tanaka F, Hasegawa S et al.. A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma. Jpn J Clin Oncol 2009; 39: 186-188.
7. Weder W, Stahel RA, Bernhard J et al.. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
8. Rea F, Marulli G, Bortolotti L et al.. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007; 57: 89-95.
9. Krug LM, Pass HI, Rusch VW et al.. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-3013.
10. De Perrot M, Feld R, Cho BC et al.. Trimodalitiy therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418.
11. Van Schil PE, Baas P, Gaafar R et al.. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicenter trial. Eur Respir J 2010; 36: 1362-1369.
12. Treasure T, Lang-Lazdunski L, Waller D et al.. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-772.
13. Ceresoli GL, Chiti A, Zucali PA et al.. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose. J Clin Oncol 2006; 24: 4587-4593.
14. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12.
15. Lee JR, Madsen MT, Bushnel D et al.. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000; 21: 685-690.
16. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
17. Cao CQ, Yan TD, Bannon PG et al.. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 1692-1703.
18. van Klaveren RJ, Aerts JG, de Bruin H et al.. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43: 63-69.
19. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006; 33: S27-S37.
20. Sugarbaker DJ, Flores RM, Jaklitsch MT et al.. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
21. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68: 1799-1804.
22. Okada M, Mimura T, Ohbayashi C et al.. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008; 7: 102-106.
23. Flores RM, Pass HI, Seshan VE et al.. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-626.